Literature DB >> 8289210

Antibiotic-induced release of endotoxin from bacteria in vitro.

H A Crosby1, J F Bion, C W Penn, T S Elliott.   

Abstract

The ability of cefotaxime, ciprofloxacin, piperacillin and tobramycin to cause release of endotoxin was examined in vitro with cultures of Enterobacter cloacae and Escherichia coli. Endotoxin was measured by a quantitative limulus amoebocyte lysate assay and its presence was confirmed by silver staining of the lipopolysaccharide moiety following SDS-PAGE. The morphology of the bacteria during antibiotic exposure was examined by scanning electronmicroscopy. Cefotaxime, ciprofloxacin and piperacillin caused significant endotoxin release, correlating with their ability to affect cell-wall morphology, causing filamentation, wall breakage and cell lysis. In contrast, little endotoxin was released when bacteria were exposed to tobramycin and no morphological changes were observed when bacteria were exposed to bactericidal concentrations of this aminoglycoside. Its antimicrobial spectrum and bactericidal activity make tobramycin an appropriate agent for treatment of sepsis caused by gram-negative bacteria and its lack of propensity to elicit excessive release of endotoxin may avoid exacerbation of endotoxin-related shock in sepsis.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8289210     DOI: 10.1099/00222615-40-1-23

Source DB:  PubMed          Journal:  J Med Microbiol        ISSN: 0022-2615            Impact factor:   2.472


  22 in total

1.  Pharmacodynamic effects of subinhibitory concentrations of rufloxacin on bacterial virulence factors.

Authors:  P C Braga; M T Sala; M Dal Sasso
Journal:  Antimicrob Agents Chemother       Date:  1999-05       Impact factor: 5.191

Review 2.  Antiendotoxin strategies for the prevention and treatment of septic shock. New approaches and future directions.

Authors:  S M Opal; R L Yu
Journal:  Drugs       Date:  1998-04       Impact factor: 9.546

Review 3.  The significance of endotoxin release in experimental and clinical sepsis in surgical patients--evidence for antibiotic-induced endotoxin release?

Authors:  R G Holzheimer
Journal:  Infection       Date:  1998 Mar-Apr       Impact factor: 3.553

4.  Differential induction of pro- and anti-inflammatory cytokines in whole blood by bacteria: effects of antibiotic treatment.

Authors:  J T Frieling; J A Mulder; T Hendriks; J H Curfs; C J van der Linden; R W Sauerwein
Journal:  Antimicrob Agents Chemother       Date:  1997-07       Impact factor: 5.191

5.  Differential release of smooth-type lipopolysaccharide from Pseudomonas aeruginosa treated with carbapenem antibiotics and its relation to production of tumor necrosis factor alpha and nitric oxide.

Authors:  T Yokochi; A Kusumi; N Kido; Y Kato; T Sugiyama; N Koide; G Z Jiang; K Narita; K Takahashi
Journal:  Antimicrob Agents Chemother       Date:  1996-10       Impact factor: 5.191

Review 6.  Antibiotic-induced release of endotoxin. A therapeutic paradox.

Authors:  J C Hurley
Journal:  Drug Saf       Date:  1995-03       Impact factor: 5.606

Review 7.  Programmed death in bacteria.

Authors:  K Lewis
Journal:  Microbiol Mol Biol Rev       Date:  2000-09       Impact factor: 11.056

8.  Pharmacodynamic evaluation of the neutralization of endotoxin by PMX622 in mice.

Authors:  Philip Lake; Jeffrey DeLeo; Franklin Cerasoli; Lennart Logdberg; Marla Weetall; Dean Handley
Journal:  Antimicrob Agents Chemother       Date:  2004-08       Impact factor: 5.191

Review 9.  Receptors, mediators, and mechanisms involved in bacterial sepsis and septic shock.

Authors:  Edwin S Van Amersfoort; Theo J C Van Berkel; Johan Kuiper
Journal:  Clin Microbiol Rev       Date:  2003-07       Impact factor: 26.132

10.  Release of tumor necrosis factor alpha and interleukin 6 during antibiotic killing of Escherichia coli in whole blood: influence of antibiotic class, antibiotic concentration, and presence of septic serum.

Authors:  J M Prins; E J Kuijper; M L Mevissen; P Speelman; S J van Deventer
Journal:  Infect Immun       Date:  1995-06       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.